YESINTEK (USTEKINUMAB)
YESINTEK (USTEKINUMAB) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: YESINTEK; Generic name: USTEKINUMAB; Drug class: Interleukin-12 Antagonist [EPC].
| Brand name | YESINTEK |
|---|---|
| Generic name | USTEKINUMAB |
| Drug class | Interleukin-12 Antagonist [EPC] |
| Manufacturer | Biocon Biologics Inc. |
| Used for | 1 INDICATIONS AND USAGE YESINTEK is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn’s disease (CD ). ( 1.3 ) moderately to severely active ulcerative colitis . ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis (PsO) , who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) 1.1 Plaque Psoriasis (PsO) YESINTEK is indicated for the treatment of adults and pediatric patients 6 ye |
| Dosage | 2 DOSAGE AND ADMINISTRATION Adult Patients with Plaque Psoriasis Subcutaneous Recommended Dosage ( 2.1 ) : Weight Range (kilograms) Dosage less than or equal to 100 kg 45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks greater than 100 kg 90 mg administered subcutaneously initially and 4 weeks later, followed by 90 mg administered subcutaneously every 12 weeks Pediatric Patients 6 Years of Age and Older with Plaque Psoriasi |
| Active ingredient(s) | USTEKINUMAB |
| Route | SUBCUTANEOUS |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12a75613-ee33-d30a-215b-2a51cfa19b00 |